Hillsboro, OR, United States of America

Andalib Khan

This inventor holds 2 USPTO granted patents. Top assignee: Intel Corporation. Active years: 2006-2011.


% Patents Active = 50.0

Average Co-Inventor Count = 9.0

ph-index = 2

Forward Citations = 20(Granted Patents)


Company Filing History:


Years Active: 2006-2011

Loading Chart...
2 patents (USPTO):Explore Patents

Title: The Innovations of Andalib Khan

Introduction: Andalib Khan is an accomplished inventor based in Hillsboro, OR (US). He has made significant contributions to the field of technology, particularly in link layer systems. With a total of 2 patents to his name, Khan continues to push the boundaries of innovation.

Latest Patents: One of his latest patents is a link level retry scheme. This invention provides a link layer system that includes a first link layer control module and a retry queue for storing a transmitted data packet. The retry control module is coupled to the first link layer control module, which directs the retry queue to discard the transmitted data packet when an acknowledgment bit is received by the first link layer control module. This innovative approach enhances the efficiency of data transmission.

Career Highlights: Andalib Khan has built a successful career at Intel Corporation, where he has been instrumental in developing advanced technologies. His work has not only contributed to the company's success but has also had a lasting impact on the industry.

Collaborations: Throughout his career, Khan has collaborated with talented individuals such as Suresh S Chittor and Phanindra Mannava. These partnerships have fostered a creative environment that encourages innovation and the development of groundbreaking technologies.

Conclusion: Andalib Khan's contributions to the field of technology through his patents and collaborations highlight his role as a leading inventor. His work continues to inspire future innovations in link layer systems and beyond.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…